AGC Biologics expands its partnership with Novavax.

Read: Work on matrix-M adulents for Novavax for the new COVID-19 vaccine ™ expanded to Seattle.
12, 2020, the Global Biopharmaceutical Contract Development and Production Organization (CDMO) AGC Biologics announced that it had expanded its relationship with Novavax, Inc. (NASDAQ: NVAX) (Novavax), a late-stage biotechnology company that develops a new generation of vaccines for serious infectious diseases.
AMC Biologics is currently preparing to manufacture Matrix-M™ at its Copenhagen facility, which is part of the Avavac coronavirus vaccine NVX-CoV2373.
now expand to its Seattle facility to supply Matrix-M adulents to ensure U.S. supplies.
NVX-CoV2373 is a stable pre-fusion protein made using Novavac's own nanoparticle technology.
AMC Biologics will optimize process development for Therix-M's expanded production, allowing Novavax to make significant global supplies in 2020 and 2021.
mark Womack, chief commercial officer at AMC Biologics, said: "We are very pleased that Novavax has asked us to expand production of its coronavirus vaccine NVX-CoV2373 in Seattle.
this allows us to provide further support to meet the needs of Novavax, which needs extraordinary urgency to advance the vaccine.
. Hahn, Novavac's senior vice president of process technology, said, "We are excited to expand our partnership with AMC Biologics to the United States.
AMC Biologics has established them as key partners in our NVX-CoV2373 adulent supply chain and we are very grateful to them for demonstrating a high level of commitment and flexibility in meeting the urgent needs of this project.
Patricio Massera, chief executive of AGC Biologics, said: "We are delighted to take this opportunity to serve Novavax at another facility in our global network and to do more in the fight against the coronavirus epidemic.
" global network of AGC Biologics spans three continents, with facilities in Seattle, Washington, Bolton, Colorado, Copenhagen, Denmark, Heidelberg, Italy, Milan, Italy, and Chiba, Japan.
company's outstanding services include the development and manufacture of therapeutic proteins, proton DNA, viral vectors and genetically engineered cells based on mammals and microorganisms.
.